Biothrax

Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax

 

Submitted by admin on Thu, 07/07/2011 - 14:59. categories [ ]

Emergent BioSolutions Reports Financial Results for Full Year 2010

  • 2010 revenues of $286.2 million
  • 2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability
  • 2010 cash, investments and accounts receivable balance of $210.4 million
  • 2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million

Emergent BioSolutions Inc. (NYSE: EBS) announced on 10 March its financial results for the full year ending December 31, 2010.

Submitted by admin on Wed, 06/22/2011 - 12:51. categories [ ]

Emergent BioSolutions' Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

 

Submitted by admin on Fri, 06/10/2011 - 13:57. categories [ ]

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule

ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S.
Submitted by admin on Tue, 06/07/2011 - 15:20. categories [ ]

Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Th

New Contract Valued at up to $28.7 Million for Phase II Clinical Trial

Submitted by admin on Fri, 09/10/2010 - 13:50. categories [ ]

Emergent Revises Upward 2010 Financial Forecast

Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million

Submitted by admin on Tue, 08/03/2010 - 10:35. categories [ ]

Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax

ROCKVILLE, Md., Jul 14, 2010

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale manufacturing of BioThrax(R) (Anthrax Vaccine Adsorbed) in Building 55. Building 55 is the company’s large-scale state-of-the-art vaccine manufacturing facility in Lansing, Michigan.

Submitted by admin on Thu, 07/15/2010 - 15:53. categories [ ]

Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments

ROCKVILLE, MD, June 24, 2010 – Emergent BioSolutions Inc.

Submitted by admin on Wed, 07/07/2010 - 12:00. categories [ ]